(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride is a bicyclic proline analog featuring a fused cyclopropane ring. This specific stereoisomer is a key chiral intermediate in the synthesis of novel pharmaceutical compounds. Its rigid, three-dimensional structure is valuable for modulating the biological activity and pharmacokinetic properties of target molecules. Its primary and most significant application is in the research and development of anticancer drugs. It serves as a crucial building block for the synthesis of KRAS G12C inhibitors, a prominent class of targeted therapies. Specifically, it is a vital intermediate in the manufacturing process of Sotorasib (AMG 510), the first FDA-approved KRAS G12C inhibitor for treating non-small cell lung cancer (NSCLC). The compound's structure is integral to forming the core scaffold of these inhibitors. As a high-value pharmaceutical intermediate, its production and quality are strictly controlled to meet Good Manufacturing Practice (GMP) standards. Handling requires standard laboratory precautions for fine chemicals. Its importance lies in enabling the efficient and stereoselective synthesis of complex, life-saving oncology therapeutics.